The addition of cladribine was associated with higher rates of CR (67.5% vs 56% [P = 0.01]) and 3-year survival (45% vs 33% [P = 0.02]) compared with “3+7” regimen alone (36) and also improved outcome in FLT3-mutated AML (37). Here, FLT3 is linked to acute myeloid leukemia.